US biotech Illumina faces steep loss from forced sale of Grail
Shares in cancer-test developer trading in low volumes ahead of spin-off demanded by antitrust regulators
Shares in cancer-test developer trading in low volumes ahead of spin-off demanded by antitrust regulators